Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Patent
1992-07-29
1998-06-23
Elliott, George C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
424 932, 435 693, 4353201, A61K 3921, A61K 39295, C12N 1586, C12P 2102
Patent
active
057702101
ABSTRACT:
A recombinant vaccinia virus capable of expressing HTLV-III envelope protein (env) has been constructed. The expressed env protein is recognized by sera obtained from AIDS patients. The synthesized env protein also produces antibodies when administered to a suitable host, such antibodies having specific binding affinity with the env protein.
REFERENCES:
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 5081029 (1992-01-01), Zarling et al.
Cremer et al., (1985) Science 228:737-740.
Mackett et al., (1985) Science 227:433-435.
Wicktor et al., (1984) Proc. Natl. Acad. Sci. USA 81:7194-98.
Moss et al., (1984) Nature 311:67-69.
Wain-Hobson et al., (1985) Cell 40:9-17.
Sanchez-Pescador et al., (1985) Science 227:484-492.
Ratner et al., (1985) Nature 313:277-284.
Muesing et al., (1985) Nature 313:450-458.
Robey et al., (1985) Science 228:593-595.
Veronese et al., (1985) Science 229:1402-1405.
Crowl et al., (1985) Cell 41:979-986.
Panicali et al., (1983) Proc. Natl. Acad. Sci. USA 80:5364-68.
Smith et al., (1983) Proc. Natl. Acad. Sci. USA 80:7155-7159.
Lizhong et al., "Expression of the M Gene of Vesicular Stomatitis Virus Cloned in Various Vaccinia Virus Vectors", Journal of Virology vol. 62: Mar. 1988, pp. 776-782.
Lifson et al., "Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein", Nature, vol. 323, Oct. 23, 1986, pp. 725-728.
Sodroski et al., "A second post-transcriptional trans-activator gene required for HTLV-III replication", Nature, vol. 321, May 22, 1986, pp. 412-417.
Peterlin et al., "Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus", Proc. Natl. Acad. Sci. USA, vol. 83, Dec. 1986, pp. 9734-9738.
Rosen et al., "Post-transciprtional regulation accounts for the trans-activation of the human T-lymphotropic virus type III", Nature, vol. 319, Feb. 13, 1986, pp. 555-559.
Langford et al., "Anchoring a Secreted Plasmodium Antigen on the Surface of Recombinant Vaccinia Virus-Infected Cells Increases Its Immunogenicity", Molecular and Cellular Biology vol. 6: Sep. 1986, pp. 3191-3199.
Berman et al., "Expression of Membrance-Associated and Secreted Variants of gp160 of Human Immunodeficiency Virus Type 1 in Vitro and in Continuous Cell Lines", Journal of Virology vol. 62: Sep. 1988, pp. 3135-3142.
Falkner et al., "Use of Vaccinia Virus Vectors to Study the Synthesis, Intracellular Localization, and Action of the Human Immunodeficiency Virus Trans-Activator Protein", Virology 164, pp. 450-457 (1988).
Elango, N. et al (1986) Proc. Natl. Acad. Sci. USA 83:1906-1910.
Stephens, E.B. et al (1986) The EMBO Journal 5:237-245.
Mackett, M. et al. (1985) The EMBO Journal 4:3229-3234.
Chakrabarti Sekhar
Moss Bernard
Elliott George C.
Railey II Johnny F.
The United States of America as represented by the Department of
LandOfFree
Recombinant vaccinia virus expressing human retrovirus gene does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant vaccinia virus expressing human retrovirus gene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant vaccinia virus expressing human retrovirus gene will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1392555